全球药物研发服务市场 – 行业趋势及 2030 年预测

药物研发服务市场分析及规模

根据美国癌症协会的数据，2020 年美国诊断出约 180 万例新癌症病例，估计有 606,520 人死于癌症。因此，疾病负担的增加及其全球负担推动了对药物发现服务的需求。为了更好地识别候选药物，生物信息学、高通量和组合化学等先进技术的使用有所增加。随着新兴技术的出现，药物发现有了显著的发展，使这一过程更加精细、准确和耗时。

Data Bridge Market Research 分析，药物发现服务市场在 2022 年为 146.8 亿美元，预计到 2030 年将达到 449.1 亿美元，在 2023 年至 2030 年的预测期内复合年增长率为 15.00%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

药物研发服务市场范围和细分

Market Definition

Drug discovery is the process of identifying a compound that can be used to treat and cure diseases. A drug discovery effort typically addresses a biological target that has been shown to play a role in disease development or begins with a molecule with interesting biological activities. Drug discovery has recently evolved significantly as a result of emerging technologies, allowing the process to become more refined, accurate, and time-consuming.   Drugs were discovered by identifying the active ingredient in traditional remedies or by chance, as in the case of penicillin.

Global Drug Discovery Services Market Dynamics

Drivers

• Rising demand for novel therapies for various therapeutic purposes

Drug discovery services market growth is expected to be driven by rising demand for novel medicine for chronic diseases and development in the global healthcare sector. Pharmaceutical and biopharma companies continue to outsource their research and development activities to contract research organisations (CROs), which provides R&D services and develop engagement models to maximise R&D productivity. The rising burden of chronic diseases is compelling governments and pharmaceutical companies to seek solutions and increase investment in clinical trials. As a result, the demand for drug discovery services will increase.

• Rising chronic disease burden

Chronic conditions such as diabetes, dementia, and cardiovascular disease have high socioeconomic costs and a high and rising patient illness burden. They cause seven out of every ten fatalities worldwide, accounting for more than 40 million deaths yearly. Chronic diseases, which are the leading causes of death and disability in the United States, account for the majority of healthcare costs. As a result, the global market for drug discovery services is expected to be driven by the prevalence of chronic diseases over the forecast period, resulting in an increase in R&D spending and research activities for developing novel drugs. There is a high demand for medications due to the increased prevalence of these chronic diseases which creates new economic opportunities for companies that provide drug discovery services.

Opportunities

• Increasing spending on R&D activities

The biopharmaceutical industry's increased R&D spending is driving demand for clinical trial and analytical test outsourcing. The global drug discovery services market is being propelled forward by increased research efforts on orphan pharmaceuticals and uncommon research diseases. The growing demand for biopharmaceutical treatments is propelling the biologics industry forward globally. Biopharmaceuticals alone account for approximately 20% of the pharmaceutical industry. The development of numerous novels and effective life-saving biologics treatments has increased demand. Biologics companies are encouraged to invest in developing new drugs for a wide range of common and uncommon diseases. Furthermore, patent expiration and rising demand for biologics in emerging markets propel the global drug discovery services market.

Restraints/Challenges

• High cost of drug molecules

A lack of skilled labor and a high target drug molecule failure rate will be the major impediments to the market. The drug development costs are high as millions of dollars are spent in preclinical research to identify a compound or design a drug.

This drug discovery services market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drug discovery services market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Drug Discovery Services Market

The SARS-sudden CoV-2's emergence and spread prompted international multilateral organizations and private funders to pool their resources to support the development of an effective vaccine to combat the coronavirus and its variants. Around the world, a large number of scientists, technologists, and data managers are involved in everything from laboratory investigations to clinical trials. The COVID-19 intervention has assisted the government and healthcare sectors in understanding the importance of drug discovery in developing effective medications. As a result, many businesses have increased their R&D spending, and the government has prioritized drug discovery and development, which positively impacts the market for drug discovery services.

Countries' health systems are rapidly investing in research and development to combat the COVID-19 pandemic. Potential compounds were selected from the CHEMBL, ZINC, FDA-approved drugs, and clinical trial molecules. Worldwide, research teams are identifying drugs for the treatment of COVID-19 by screening both novel and existing drugs for their ability to alleviate symptoms and halt viral replication. As a result of the ongoing pandemic, the drug discovery services market is expected to benefit from the desire to find a cure for COVID-19.

Recent developments

• On December 3, 2021, Toxikon Corporation, a contract research company, acquired by Labcorp. Toxikon's acquisition is expected to broaden the company's product portfolio.
• On January 25, 2022, Evotec and Boehringer Ingelheim formed a target and drug development collaboration focused on iPSC-based disease modelling for ophthalmologic illnesses.

Global Drug Discovery Services Market Scope

The drug discovery services market is segmented on the basis of type, process, drug type and therapeutic area. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Medicinal Chemistry Services
• Biology Services
• Drug Metabolism and Pharmacokinetics

Process

• Target Validation
• Target Selection
• Hit-To-Lead Identification
• Candidate Validation
• Lead Optimization

 Drug Type

• Biologics
• Small Molecules

 Therapeutic Area

• Neurology
• Diabetes
• Oncology
• Respiratory Diseases
• Cardiovascular Diseases
• Others

Drug Discovery Services Market Regional Analysis/Insights

The drug discovery services market is analysed and market size insights and trends are provided by country, type, process, drug type and therapeutic area as referenced above.

The countries covered in the drug discovery services market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the drug discovery services market because of the availability of cutting-edge techniques, instruments, and facilities for drug discovery research in this region due to many qualified researchers and low-cost operations in emerging countries such as India and China.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the strong presence of well-established CROs, and rising R&D expenditure by pharmaceutical and biopharmaceutical companies.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和药物发现服务市场份额分析

药物发现服务市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对药物发现服务市场的关注有关。

药物研发服务市场的一些主要参与者包括：

• 通用电气（美国）
• Eurofins Scientific（美国）
• PPD Inc.（美国）
• Syngene International Limited（印度）
• 无锡药明康德 (中国)
• Frontage Labs（美国）
• 加拉帕戈斯群岛 NV（比利时）
• Aurigene Discovery Technologies（印度）
• Genscript (美国)
• Domainex（英国）
• WIL 研究实验室有限责任公司 (美国)
• 上海美迪西生物医药股份有限公司 (中国)
• Labcorp 药物开发（美国）
• Jubilant Biosys Ltd.（印度）
• Evotec（德国）
• 上海睿智化学有限公司（中国）
• Charles River Laboratories（美国）
• 默克公司（美国）
• 赛默飞世尔科技公司（美国） 

SKU-57114